Product Name: Flt1 (1045-1051) pY1048
Product Number: PE-04BBL00
Size: 200 µg      Price:35.00
1 mg      $US70.00
Peptide Name: Flt1 (1045-1051) pY1048

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y1048 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RDI-pY-KNP

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 983.99 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Storage Stability: stable

Scientific Background: VEGFR1 (Flt1) is a protein-tyrosine kinase of the TK group and VEGFR family. It functions as a membrane receptor for VEGFA, VEGFB, and PGF. Binding vascular endothelial growth factor (VEGF), which induces dimerization and autophosphorylation. Autophosphorylation of Y1169 induces interaction with PLCg1. Autophosphorylation of Y1213 increases phosphotransferase activity and induces interaction with Grb2, PLCg1 and SHP2. Autophosphorylation ofY1333 induces interaction with Cbl, Crk, Nck1 and PLCg1. VEGFR1 is critical for the development of embryonic vasculature, angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. In adulthood, VEGFR1 promotes endothelial cell proliferation, survival, and angiogenesis. In addition, the VEGFR1 protein mediates the activation of the MAPK and Akt1 intracellular signalling pathways, as well as directly phosphorylates Src, Yes1, and possibly Cbl. VEGFR1 appears to be an oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. Gain-of-function mutations in the VEGFR1 gene are associated with cancer development. VEGFR1 expression has been shown to contribute to cancer cell survival, proliferation, migration, tissue invasion, tumour angiogenesis, and metastasis. In addition, VEGFR1 may promote cancer pathogenesis by enhancing inflammatory responses and recruiting tumour-infiltrating macrophages.